started · updated
Latvian family seeks 240,000 euros for rare disease treatment
A three-year-old girl in Latvia, Olīvija, has been diagnosed with CLN2 (type 2 neuron ceroid lipofuscinosis), a rare and severe genetic disease that causes brain atrophy and progressive loss of motor and speech skills. Without treatment, children with this condition typically lose independence by age four or five and may face blindness or death by age ten.
To delay the progression of the disease, doctors have prescribed the medication Brineura, which must be administered every two weeks for life. The charity organization ‘Ziedot.lv’ has launched a fundraising campaign to secure at least 240,000 euros, which would cover the first six months of treatment. The total annual cost of the therapy is estimated at approximately 480,000 euros.
The medication is not currently included in the Latvian state-compensated drug list. While the family has approached state institutions to seek government funding, no solution has been reached. Medical professionals are currently in contact with the drug manufacturer to discuss pricing and training for ongoing therapy.